Getting more press - SeekingAlpha posted this update just now.

Maybe the F50s want to keep the price down?

http://additivemanufacturing.com/2017/02/28/morf3d-bolsters-additive-manufacturing-capabilities-with-investment-in-eos-systems/

Yep, I'm anxious for reinstatement!

Disregard - it's the wrong listing.

In a Merge Dissolved status. It's
not clear to me what this means going forward.

Showing active now:
https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=pwsp9sIxtajTgRdc4wdBsQ%253d%253d&nt7=0

SIGMA LABS TO RING THE NASDAQ STOCK MARKET OPENING BELL ON THURSDAY, MARCH 2

There is a 2nd listing under NV SOS for Nyxio: https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=pwsp9sIxtajTgRdc4wdBsQ%253d%253d&nt7=0

Merge Dissolved back in 2011.

New Tweet: Nyxio has retained an SEC law firm to assist with the company's cleanup, turnaround, and getting current.

Here's the link to NV SOS: https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=l%252bVZUswp3F3oXjmno4UWRw%253d%253d

Nothing is current.

From M Landfer's Post: Watching for her to go "Active" like a hawk here.. https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=l%252bVZUswp3F3oXjmno4UWRw%253d%253d

Then select the " Calc Reinstatement Fee" button.

NYXO

I see that Giorgio owes $10.7K in reinstatement fees.

Presidents' Day Schedule

US Markets, Monday, February 20, 2017
All US markets (including equity, option, and fixed income) will be closed in observance of Presidents' Day
There will be no Pre-Market or After Hours trading sessions.

Notice of Effectiveness just released.

Me too! It's not tradable on Schwab or OptionsExpress.

Thanks & a new tweet just came out: We hoped to have a press issued this week, but there's been a slight delay with the announcement. Updates imminent! $NYXO

That link gave a 404: Page Not Found error.

http://www.fool.com/investing/2017/01/26/what-to-expect-in-organovo-holdings-inc-q3-results.aspx

How do you trade just one share of a trip?

A company tweet would be nice right about now...

Picked up some shares & hoping for some positive news soon.

New article: http://www.economist.com/news/science-and-technology/21715638-how-build-organs-scratch

Related to SGLB, but no specific reference: https://pennystockresearch.com/3-3d-printing-stocks-that-could-catch-fire/

Current Generation 3D Metal Powder Bed Systems: An Unstable System Process
https://www.linkedin.com/pulse/current-generation-3d-metal-powder-bed-systems-system-louis-schlegel

Just out:
Organovo Collaborates With Professor Melissa Little for Kidney Tissue Research

SAN DIEGO and MELBOURNE, Australia and SPRINGFIELD, Va., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced a collaboration with Professor Melissa Little and the Murdoch Childrens Research Institute, The Royal Children’s Hospital, Melbourne, Australia to develop an architecturally correct kidney for potential therapeutic applications. The collaboration has been made possible by a generous gift from the Methuselah Foundation (“Methuselah”) as part of its ongoing University 3D Bioprinter Program.

“Partnerships with world-class institutions can accelerate groundbreaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues," said Keith Murphy, CEO, Organovo. “This collaboration with Professor Little’s lab is another important step in this direction. With the devoted and ongoing support of the Methuselah Foundation, leading researchers are able to leverage Organovo’s powerful technology platform to achieve significant breakthroughs.”

“We have developed an approach for recreating human kidney tissue from stem cells,” said Professor Melissa Little, Theme Director of Cell Biology at Murdoch Childrens Research Institute. “Using Organovo’s bioprinter will give us the opportunity to bioprint these cells into a more accurate model of the kidney. While initially important for modelling disease and screening drugs, we hope that this is also the first step towards regenerative medicine for kidney disease. We are very grateful to Organovo and the Methuselah Foundation for this generous support, which will enable us to advance our research with the first Organovo bioprinter in the southern hemisphere.”

Under Methuselah Foundation's University 3D Bioprinter Program, Methuselah is donating at least $500,000 in direct funding to be divided among several institutions for Organovo bioprinter research projects. This funding will cover budgeted bioprinter costs and key aspects of project execution.

"We at the Methuselah Foundation have been a long-time supporter of academic and industry research in 3D bioprinting, regenerative medicine, and tissue engineering," said David Gobel, CEO, Methuselah Foundation. "Our University 3D Bioprinter Program puts Organovo’s breakthrough 3D bioprinting technology in the hands of the brightest scientists at tissue engineering centers of excellence."

Organovo Announces Release Date for Fiscal Third-Quarter 2017 Financial Results

SAN DIEGO, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, will host a conference call on Thursday, February 9, 2017 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal third-quarter 2017 financial results. In advance of the call on February 9, 2017, Organovo will issue its fiscal third-quarter 2017 earnings press release, which will be available at http://www.organovo.com. To participate in the teleconference, callers can dial the following numbers:

1-888-317-6003 (toll-free, U.S. callers only)

1-412-317-6061 (from outside the U.S.)

Conference Call ID: 1376489

To help ensure the conference call begins in a timely manner, please dial in five minutes prior to the scheduled start time. The conference call will also be simultaneously webcast at http://www.organovo.com.

For those unable to participate in the live call, a replay of the call will be available toll-free until February 16, 2017 at 1-877-344-7529 (U.S. callers only) or at 1-412-317-0088 (callers outside the U.S.). The passcode for the replay is: 10100036. An archived replay of the webcast will also be available at http://www.organovo.com.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the market acceptance of the Company's products and services; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, including its use of third party distributors; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships; the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all; and the Company’s ability to meet its fiscal year 2017 outlook and/or its long-range outlook. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2016 and its Quarterly Report on Form 10-Q filed with the SEC on November 3, 2016. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

Investor Contact:

Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com

Press Contact:

Jessica Yingling
Little Dog Communications
+1 (858) 480-2411
jessica@litldog.com
Primary Logo

Organovo, Inc.

Looks like a much needed concerted effort to lift the stock price going into the last week of the year. We need it!

This was posted on SGLB's Facebook page. Do your dot connecting with the Siemen's reference:

http://www.designworldonline.com/additive-manufacturings-bright-future/#_

Organovo to Present on December 14 in a Live Interactive Webcast at VirtualInvestorConferences.com
Organovo Holdings Inc has added a news release to its Investor Relations website.

Sigma Labs & PrintRite3D are highlighted in this article that was put out on LinkedIn about an hour ago:

http://www.dgiwire.com/a-worlds-record-for-aerospace-3d-printed-parts/

Yes, that's the same web page.

There's no mention of Organovo in this article, which surprises me:

Bioprinting Is One Step Closer to Making a Human Kidney
BY VANESSA BATES RAMIREZON NOV 27, 2016
Bioprinting has been all over the news in the past several years with headline-worthy breakthroughs like printed human skin, synthetic bones, and even a fully functional mouse thyroid gland.

3D printing paved the way for bioprinting thanks to the printers’ unique ability to recreate human tissue structures; their software can be written to ‘stack’ cells in precise patterns as directed by a digital model, and they can produce tissue in just hours and make numerous identical samples.

Despite the progress in bioprinting, however, more complex human organs continue to elude scientists, and resting near the top of the ‘more complex’ list are the kidneys.

Kidney basics

The kidneys, bean-shaped and fist-sized, are located below the rib cage on either side of the spine and play a critical role in our day-to-day health. Each kidney cleans the blood by passing fluid and waste products through a biological filter called a nephron that blocks blood cells and important molecules like proteins. Necessary minerals are passed back to the blood, and waste exits the body in urine.

Our kidneys filter 120 to 150 quarts of blood every day, keeping the blood’s composition stable and our bodies functioning properly. Our kidneys prevent waste buildup in the body, stabilize our electrolyte levels, and produce hormones to regulate blood pressure and make red blood cells.

They don’t work for everyone

About 10% of the global population is affected by chronic kidney disease, with millions of people dying each year due to lack of affordable treatment. In the US, treatment of chronic kidney disease costs around $48 billion per year, consuming almost seven percent of the total Medicare budget to care for less than one percent of the covered population. There are over 93,000 people currently on the US kidney transplant waiting list, with wait times ranging up to ten years.

Lacking a donor kidney, patients who can afford it undergo dialysis, which requires them to sit for three to ten hours as blood passes out of their bodies, through a machine that cleans it, then back into their veins. Despite the high cost and time commitment of dialysis, it still doesn’t do as good of a job of cleaning the blood as kidneys do.

A better solution may be near

The kidneys are one of the hardest organs to recreate—if not the hardest. This is due both to the huge number of nephrons contained in each kidney and to the nephrons’ intricate structure.

But scientists at Harvard’s Jennifer Lewis Lab recently took the first step towards creating an artificial kidney that could one day replace biological donor kidneys. Using 3D printing, Lewis and her colleagues were able to re-create the tubule component of the kidney’s nephrons and give it a vascular network for blood flow.

The first step was to print a 3D tissue grid made of layers of gels at room temperature. One gel contains human stem cells, and the other becomes a liquid when cooled.

As the tissue sets, it cools off, which causes the second gel to flow out of the grid, leaving behind channels where blood vessels can grow. An alternative method, developed by researchers at Wake Forest University, is to program the printer software to leave microchannels in the tissue structure.

The material is enclosed in an extracellular matrix, then growth factors are added to the hollow channels to prompt the stem cells to differentiate into specific cell types.

The 3D printed tubules were able to stay alive for over two months.

Steady progress

Last year, scientists at Lawrence Livermore National Laboratory developed a method that allows vascular networks to self-assemble in bioprinted tissues. Until that point, the vascular network was the biggest missing piece for bioprinting organs.

The kidney tissue created at Lewis Lab is significant because of the tubules’ complexity, and the fact they were partially able to function as biological nephrons do.

Bioprinting has a ways to go before being able to create a fully-functional organ, but the technology has other useful applications. Bioprinted nephron tubules could be used for drug toxicity testing, helping determine biological kidneys’ ability to filter certain chemicals, or they could be incorporated into existing dialysis methods to make the procedure more similar to the way our bodies intended.

Individual advancements in bioprinting may seem small, but if they continue at their current pace, we may see printed organs start to take the burden off those donor lists during our lifetime.

See the end of the article regarding SGLB:

https://3dprint.com/157150/formnext-2016-software-updates/

Here's the article minus the About statement added to every press release:

Organovo to Present at 28th Annual Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at the 28th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 29th at 4:00 p.m. Eastern Time (ET). The presentation will be simultaneously audio webcast at http://www.organovo.com. The audio webcast will be archived for 90 days following the conference.

Organovo to Present at 28th Annual Piper Jaffray Healthcare Conference
http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-newsArticle&ID=2225229

The PDF file of the article says it was written on Nov 17, 2016.

Sigma Labs posted this 4 hours ago on LinkedIn - it's probably posted on their Facebook page too:

http://www.dgiwire.com/industrial-internet-of-things-ensuring-quality-control-on-the-factory-floor/

It doesn't say when the article was written.

They are postings of pictures for Sigma Labs booth at Formnext. One of the captions read: Formnext 2016 in the books. Great event, Sigma's most successful show yet. This industry is on fire!! Thank you to all customers, colleagues and friends.

https://www.linkedin.com/hp/update/6205473876823064576
& https://www.linkedin.com/hp/update/6205474212585500673